|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
NZ503788A
(en)
*
|
1997-10-27 |
2002-11-26 |
Agouron Pharma |
4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases
|
|
AU763839B2
(en)
*
|
1998-05-26 |
2003-07-31 |
Warner-Lambert Company |
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
|
|
EP1801112A1
(en)
*
|
1998-05-26 |
2007-06-27 |
Warner-Lambert Company LLC |
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
|
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
BR9911365A
(pt)
|
1998-06-19 |
2001-03-13 |
Pfizer Prod Inc |
Compostos pirrolo[2,3-d]pirimidina
|
|
ES2274634T3
(es)
|
1998-08-29 |
2007-05-16 |
Astrazeneca Ab |
Compuestos de pirimidina.
|
|
US6632820B1
(en)
|
1998-08-29 |
2003-10-14 |
Astrazeneca Ab |
Pyrimidine compounds
|
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
|
US6399633B1
(en)
|
1999-02-01 |
2002-06-04 |
Aventis Pharmaceuticals Inc. |
Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
|
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
|
US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
|
CA2386955A1
(en)
*
|
1999-11-22 |
2001-05-31 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
|
EP1382339B1
(en)
|
1999-12-10 |
2007-12-05 |
Pfizer Products Inc. |
Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
|
|
YU54202A
(sh)
|
2000-01-18 |
2006-01-16 |
Agouron Pharmaceuticals Inc. |
Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
|
|
HN2001000008A
(es)
|
2000-01-21 |
2003-12-11 |
Inc Agouron Pharmaceuticals |
Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
|
|
KR20020070520A
(ko)
*
|
2000-01-27 |
2002-09-09 |
워너-램버트 캄파니 |
신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체
|
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
PL358271A1
(pl)
*
|
2000-03-06 |
2004-08-09 |
Warner-Lambert Company |
5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny
|
|
GB0007371D0
(en)
*
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
JP2004501083A
(ja)
|
2000-04-18 |
2004-01-15 |
アゴーロン・ファーマシューティカルズ・インコーポレイテッド |
プロテインキナーゼを阻害するためのピラゾール
|
|
KR100423899B1
(ko)
|
2000-05-10 |
2004-03-24 |
주식회사 엘지생명과학 |
세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
|
|
IL152771A0
(en)
|
2000-06-26 |
2003-06-24 |
Pfizer Prod Inc |
PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
|
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
|
EP1307462A2
(en)
|
2000-08-09 |
2003-05-07 |
Agouron Pharmaceuticals, Inc. |
Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
|
|
ATE295354T1
(de)
|
2000-08-18 |
2005-05-15 |
Agouron Pharma |
Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
|
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
|
ATE521353T1
(de)
|
2000-10-23 |
2011-09-15 |
Glaxosmithkline Llc |
Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
|
|
US6756374B2
(en)
|
2001-01-22 |
2004-06-29 |
Hoffmann-La Roche Inc. |
Diaminothiazoles having antiproliferative activity
|
|
DE60206363T2
(de)
|
2001-02-12 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
6-substituierte pyridopyrimidine
|
|
GB0103926D0
(en)
*
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
|
MXPA03007623A
(es)
*
|
2001-02-26 |
2003-12-04 |
Tanabe Seiyaku Co |
Derivado de piridopirimidina o naftiridina.
|
|
KR100874791B1
(ko)
*
|
2001-05-29 |
2008-12-18 |
바이엘 쉐링 파마 악티엔게젤샤프트 |
Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
|
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
|
ES2251677T3
(es)
|
2002-01-22 |
2006-05-01 |
Warner-Lambert Company Llc |
2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
US7442697B2
(en)
|
2002-03-09 |
2008-10-28 |
Astrazeneca Ab |
4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
|
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
KR20040103972A
(ko)
|
2002-04-19 |
2004-12-09 |
스미스클라인 비참 코포레이션 |
신규 화합물
|
|
CA2492112A1
(en)
*
|
2002-08-06 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
|
|
AU2003275681B8
(en)
*
|
2002-10-29 |
2009-03-26 |
Msd K.K. |
Novel quinoxalinone derivatives
|
|
AU2003291310A1
(en)
|
2002-11-06 |
2004-06-03 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds and use thereof
|
|
NZ539901A
(en)
|
2002-11-26 |
2007-09-28 |
Pfizer Prod Inc |
Method of treatment of transplant rejection
|
|
BR0316680A
(pt)
*
|
2002-11-28 |
2005-10-18 |
Schering Ag |
Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
|
|
CN100420687C
(zh)
*
|
2002-12-20 |
2008-09-24 |
霍夫曼-拉罗奇有限公司 |
作为选择性kdr和fgfr抑制剂的吡啶并[2,3-d]嘧啶衍生物
|
|
US7098332B2
(en)
*
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
|
EP1590341B1
(en)
*
|
2003-01-17 |
2009-06-17 |
Warner-Lambert Company LLC |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
|
US7157455B2
(en)
*
|
2003-02-10 |
2007-01-02 |
Hoffmann-La Roche Inc. |
4-Aminopyrimidine-5-one derivatives
|
|
EP1622910A1
(en)
|
2003-05-05 |
2006-02-08 |
F. Hoffmann-La Roche Ag |
Fused pyrimidine derivatives with crf activity
|
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
|
CN1972712A
(zh)
|
2003-06-09 |
2007-05-30 |
塞缪尔·瓦克萨尔 |
用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
|
|
BRPI0413018B8
(pt)
|
2003-07-30 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, e, uso de um composto
|
|
RU2356901C2
(ru)
*
|
2003-07-30 |
2009-05-27 |
Райджел Фармасьютикалз, Инк. |
Соединения 2, 4-пиримидиндиамина, обладающие воздействием при аутоиммунных расстройствах
|
|
WO2005047284A1
(en)
|
2003-11-13 |
2005-05-26 |
F. Hoffmann-La Roche Ag |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
|
EP1713806B1
(en)
*
|
2004-02-14 |
2013-05-08 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
EP2332990A1
(en)
|
2004-03-19 |
2011-06-15 |
Imclone LLC |
Human anti-epidermal growth factor receptor antibody
|
|
US7211576B2
(en)
|
2004-04-20 |
2007-05-01 |
Hoffmann-La Roche Inc. |
Diaminothiazoles
|
|
AU2005316668B2
(en)
*
|
2004-12-13 |
2012-09-06 |
Millennium Pharmaceuticals, Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
|
|
MX2007008781A
(es)
|
2005-01-21 |
2007-09-11 |
Astex Therapeutics Ltd |
Compuestos farmaceuticos.
|
|
WO2006110298A2
(en)
|
2005-03-25 |
2006-10-19 |
Glaxo Group Limited |
8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
|
|
EP1865959A2
(en)
|
2005-03-25 |
2007-12-19 |
Glaxo Group Limited |
Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
|
|
UY29439A1
(es)
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
|
UY29440A1
(es)
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
|
CA2612449A1
(en)
|
2005-06-17 |
2006-12-28 |
Imclone Systems Incorporated |
Receptor antagonists for treatment of metastatic bone cancer
|
|
ATE520979T1
(de)
|
2005-08-24 |
2011-09-15 |
Bristol Myers Squibb Co |
Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
|
|
EP1931667A1
(en)
*
|
2005-09-28 |
2008-06-18 |
Ranbaxy Laboratories Limited |
Pyrido-pyridimidine derivatives useful as antiinflammatory agents
|
|
WO2007036732A1
(en)
|
2005-09-30 |
2007-04-05 |
Astrazeneca Ab |
Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
|
|
US8247408B2
(en)
*
|
2005-10-07 |
2012-08-21 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
|
|
CN101395155A
(zh)
*
|
2005-10-07 |
2009-03-25 |
埃克塞里艾克西斯公司 |
PI3Kα的吡啶并嘧啶酮抑制剂
|
|
CN101528231A
(zh)
|
2006-08-16 |
2009-09-09 |
埃克塞利希斯股份有限公司 |
在癌症的治疗中使用pi3k和mek调控剂
|
|
DK2074122T5
(da)
|
2006-09-15 |
2014-03-17 |
Pfizer Prod Inc |
Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
|
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
JP5528807B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
WO2008150260A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Gpc Biotech, Inc. |
8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
|
|
EP1914234A1
(en)
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
|
EP2142543B8
(en)
*
|
2007-04-11 |
2013-07-03 |
Exelixis, Inc. |
Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
|
|
EP2100894A1
(en)
*
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
|
WO2009132980A1
(en)
*
|
2008-04-29 |
2009-11-05 |
F. Hoffmann-La Roche Ag |
Pyrimidinyl pyridone inhibitors of jnk.
|
|
JP4884570B2
(ja)
|
2008-08-20 |
2012-02-29 |
ファイザー・インク |
ピロロ［２，３−ｄ］ピリミジン化合物
|
|
JP5619743B2
(ja)
*
|
2008-08-20 |
2014-11-05 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
エテニル置換ピリジンおよびピリミジン誘導体およびウイルス感染の治療におけるそれらの使用
|
|
WO2010039740A1
(en)
|
2008-09-30 |
2010-04-08 |
Exelixis, Inc. |
PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
|
|
JP2012505927A
(ja)
*
|
2008-10-22 |
2012-03-08 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｊｎｋのピリミジニルピリドン阻害剤
|
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
EP2408479A1
(en)
|
2009-03-18 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
|
|
EP3406260B1
(en)
|
2009-05-13 |
2020-09-23 |
The University of North Carolina at Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
EP2494070A2
(en)
|
2009-10-30 |
2012-09-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
|
US20120316187A1
(en)
|
2009-11-13 |
2012-12-13 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
UY33221A
(es)
|
2010-02-09 |
2011-09-30 |
Univ California |
MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
|
|
EP2580213A4
(en)
*
|
2010-06-09 |
2013-12-25 |
Afraxis Holdings Inc |
8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
|
|
WO2011156646A2
(en)
*
|
2010-06-09 |
2011-12-15 |
Afraxis, Inc. |
6-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
|
|
US20130252967A1
(en)
*
|
2010-06-10 |
2013-09-26 |
Afraxis, Inc. |
8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
|
|
EP2580215A4
(en)
*
|
2010-06-10 |
2014-01-15 |
Afraxis Holdings Inc |
8- (HETEROCYCYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
|
|
US8680099B2
(en)
*
|
2010-06-10 |
2014-03-25 |
Afraxis Holdings, Inc. |
6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
|
|
EP3399026B1
(en)
|
2010-06-14 |
2024-06-26 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
EP2640394A4
(en)
|
2010-11-17 |
2015-02-25 |
Univ North Carolina |
PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
SMT202400031T1
(it)
*
|
2011-04-22 |
2024-03-13 |
Signal Pharm Llc |
Diamminocarbossammide e diamminocarbonitrile pirimidine sostituite, loro composizioni e metodi di trattamento con esse
|
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
|
SG2014011316A
(en)
|
2011-08-31 |
2014-06-27 |
Genentech Inc |
Diagnostic markers
|
|
JP2014531213A
(ja)
|
2011-09-30 |
2014-11-27 |
ジェネンテック， インコーポレイテッド |
上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
|
|
WO2013056069A1
(en)
|
2011-10-13 |
2013-04-18 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
|
AU2013239816B2
(en)
|
2012-03-29 |
2017-08-24 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
WO2014151682A1
(en)
|
2013-03-14 |
2014-09-25 |
Icahn School Of Medicine At Mount Sinai |
Pyrimidine compounds as kinase inhibitors
|
|
DK2968290T3
(da)
|
2013-03-15 |
2019-11-25 |
G1 Therapeutics Inc |
Transient beskyttelse af normale celler under kemoterapi
|
|
TWI647220B
(zh)
|
2013-03-15 |
2019-01-11 |
美商西建卡爾有限責任公司 |
雜芳基化合物及其用途
|
|
HK1222766A1
(zh)
|
2013-03-15 |
2017-07-14 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
|
MY181020A
(en)
|
2013-03-15 |
2020-12-16 |
Sanofi Sa |
Heteroaryl compounds and uses thereof
|
|
EP2976085A1
(en)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
MA38393B1
(fr)
|
2014-03-13 |
2018-11-30 |
Sanofi Sa |
Composés hétéroaryle et utilisations associées
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
WO2015161285A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
SG11201609050UA
(en)
|
2014-05-30 |
2016-12-29 |
Pfizer |
Carbonitrile derivatives as selective androgen receptor modulators
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
WO2016105503A1
(en)
|
2014-12-24 |
2016-06-30 |
Genentech, Inc. |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
US9901574B2
(en)
|
2015-04-20 |
2018-02-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
|
ES2739749T3
(es)
|
2015-05-18 |
2020-02-03 |
Tolero Pharmaceuticals Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
|
MX2018001289A
(es)
|
2015-08-03 |
2018-04-30 |
Tolero Pharmaceuticals Inc |
Terapias de combinacion para el tratamiento del cancer.
|
|
CN109803968A
(zh)
|
2016-08-15 |
2019-05-24 |
辉瑞公司 |
吡啶并嘧啶酮cdk2/4/6抑制剂
|
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
WO2018119183A2
(en)
|
2016-12-22 |
2018-06-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
EP3565558B1
(en)
|
2017-01-06 |
2023-12-06 |
G1 Therapeutics, Inc. |
Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
|
|
EA201992781A1
(ru)
|
2017-05-22 |
2020-04-01 |
Эмджен Инк. |
Ингибиторы g12c kras и способы их применения
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
FI3645001T3
(fi)
|
2017-06-29 |
2024-09-25 |
G1 Therapeutics Inc |
Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
|
|
MA50077A
(fr)
|
2017-09-08 |
2020-07-15 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
WO2019213516A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
ES2995514T3
(en)
|
2018-05-04 |
2025-02-10 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
EP3790886B1
(en)
|
2018-05-10 |
2024-06-26 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
ES2929406T3
(es)
*
|
2018-05-21 |
2022-11-29 |
Nerviano Medical Sciences Srl |
Compuestos de piridonas heterocondensadas y su uso como inhibidores de IDH
|
|
ES2938987T3
(es)
|
2018-06-01 |
2023-04-18 |
Amgen Inc |
Inhibidores de KRAS G12c y métodos de uso de los mismos
|
|
US20190375749A1
(en)
|
2018-06-11 |
2019-12-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
ES3060664T3
(en)
|
2018-06-12 |
2026-03-27 |
Amgen Inc |
Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
|
RS67557B1
(sr)
|
2018-08-24 |
2026-01-30 |
Pharmacosmos Holding As |
Unapređena sinteza 1,4-diazaspiro[5.5]undekan-3-ona
|
|
EP3860608A1
(en)
|
2018-10-04 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
US11053226B2
(en)
|
2018-11-19 |
2021-07-06 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
JP7676308B2
(ja)
|
2018-12-20 |
2025-05-14 |
アムジエン・インコーポレーテツド |
Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
|
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
|
TWI844602B
(zh)
|
2018-12-20 |
2024-06-11 |
美商安進公司 |
Kif18a抑制劑
|
|
EP3898616B1
(en)
|
2018-12-20 |
2024-10-02 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
WO2020180768A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
CN113727758A
(zh)
|
2019-03-01 |
2021-11-30 |
锐新医药公司 |
双环杂环基化合物及其用途
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
NZ782284A
(en)
|
2019-05-21 |
2024-11-29 |
Amgen Inc |
Solid state forms
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP4007756B1
(en)
|
2019-08-02 |
2025-12-24 |
Amgen Inc. |
Kif18a inhibitors
|
|
WO2021026099A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
US12540129B2
(en)
|
2019-08-02 |
2026-02-03 |
Amgen Inc. |
KIF18A inhibitors
|
|
AU2020326627B2
(en)
|
2019-08-02 |
2026-01-29 |
Amgen Inc. |
KIF18A inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP4684786A3
(en)
|
2019-10-24 |
2026-04-08 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN120699039A
(zh)
|
2019-11-04 |
2025-09-26 |
锐新医药公司 |
Ras抑制剂
|
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
TW202128688A
(zh)
|
2019-11-08 |
2021-08-01 |
美商銳新醫藥公司 |
雙環雜芳基化合物及其用途
|
|
ES3033669T3
(en)
|
2019-11-08 |
2025-08-06 |
Nerviano Medical Sciences Srl |
Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
|
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
|
|
WO2021097207A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
CN114901659A
(zh)
|
2019-11-26 |
2022-08-12 |
施万生物制药研发Ip有限责任公司 |
作为jak抑制剂的稠合嘧啶吡啶酮化合物
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN114929279A
(zh)
|
2020-01-07 |
2022-08-19 |
锐新医药公司 |
Shp2抑制剂给药和治疗癌症的方法
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN113801139A
(zh)
*
|
2020-06-12 |
2021-12-17 |
华东理工大学 |
作为rsk抑制剂的嘧啶并恶嗪衍生物及其应用
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
|
MX2023003060A
(es)
|
2020-09-15 |
2023-04-05 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
|
|
US20240051956A1
(en)
|
2020-12-22 |
2024-02-15 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2022177302A1
(ko)
*
|
2021-02-17 |
2022-08-25 |
보령제약 주식회사 |
Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
AU2022268962A1
(en)
|
2021-05-05 |
2023-12-14 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023172858A1
(en)
|
2022-03-07 |
2023-09-14 |
Amgen Inc. |
A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2023358792A1
(en)
|
2022-10-14 |
2025-04-17 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
KR20260005904A
(ko)
|
2023-04-07 |
2026-01-12 |
레볼루션 메디슨즈, 인크. |
매크로사이클릭 ras 억제제
|
|
CN121263418A
(zh)
|
2023-04-07 |
2026-01-02 |
锐新医药公司 |
大环ras抑制剂
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202542151A
(zh)
|
2023-12-22 |
2025-11-01 |
美商銳格醫藥有限公司 |
Ｓｏｓ１抑制劑及其用途
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|